- Trials with a EudraCT protocol (32)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
32 result(s) found for: Atypical depression.
Displaying page 1 of 2.
EudraCT Number: 2021-003850-21 | Sponsor Protocol Number: InflaMed001 | Start Date*: 2022-08-03 |
Sponsor Name:Amsterdam UMC, location VUmc | ||
Full Title: Precision psychiatry: Anti-inflammatory medication in Immuno-metabolic depression | ||
Medical condition: Immuno metabolic Depression | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2009-011911-19 | Sponsor Protocol Number: QUE/09 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Ludwig-Maximilian-University of Munich, Department of Psychiatry | |||||||||||||
Full Title: Impact of quetiapine prolong and escitalopram on the hypothalamic-pituitary-adrenocortical (HPA)-axis activity in depressed patients | |||||||||||||
Medical condition: In this study, patients suffering from unipolar depression are investigated. 40 unipolar depressed inpatients (age 18-65) enter the study after the procedure has been fully explained and written in... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-001737-15 | Sponsor Protocol Number: D1449C00009 | Start Date*: 2005-07-18 | |||||||||||
Sponsor Name:NV AstraZeneca SA | |||||||||||||
Full Title: An open-label, non-comparative, multi-centre, phase II prospective trial to assess the efficacy of Quetiapine fumarate augmentation of selective serotonin reuptake inhibitors (SSRIs) in SSRI-resist... | |||||||||||||
Medical condition: The medical condition being treated by this protocol is single or recurrent major depressive disorder (MDD), not responding to at least one adequate SSRI treatment, however, the patients being trea... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-003867-13 | Sponsor Protocol Number: CL2-47445-014 | Start Date*: 2016-02-15 | |||||||||||
Sponsor Name:Institut de Recherches internationales Servier | |||||||||||||
Full Title: Efficacy and safety of S 47445 versus placebo as adjunctive treatment of Major Depressive Disorder in patients with an inadequate response to antidepressant therapy. A randomised, double-blind, pla... | |||||||||||||
Medical condition: Major depressive disorder | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) FI (Completed) SK (Completed) CZ (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-001718-26 | Sponsor Protocol Number: DFI10560 | Start Date*: 2010-05-07 | |||||||||||
Sponsor Name:Sanofi-Aventis Recherche & Développement | |||||||||||||
Full Title: An eight-week, multicenter, randomized, double-blind, placebo-controlled dose-finding study, with escitalopram (10mg daily) as active control, to evaluate the efficacy, safety and tolerability of t... | |||||||||||||
Medical condition: Major Depressive Disorder | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-001447-39 | Sponsor Protocol Number: AB15003 | Start Date*: 2019-10-21 |
Sponsor Name:AB SCIENCE | ||
Full Title: A 24-week with possible extension, prospective, multicenter, randomized, double blind, placebo-controlled, 2-parallel group with a randomization 1:1, phase III study to compare efficacy and safety ... | ||
Medical condition: Smouldering or Indolent Severe Systemic mastocytosis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Trial now transitioned) DE (Prematurely Ended) PL (Trial now transitioned) RO (Ongoing) LT (Completed) NL (Temporarily Halted) IT (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2006-006427-39 | Sponsor Protocol Number: D1449L00023 | Start Date*: 2007-05-18 |
Sponsor Name:AstraZeneca GmbH | ||
Full Title: The Effect of the Atypical Antipsychotic Quetiapine in the Treatment of Postpartum Depressive Disorders with or without Psychotic Symptoms | ||
Medical condition: Postpartum depressive disorders with or without psychotic symptoms | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2011-005138-21 | Sponsor Protocol Number: TC-5619-23-CRD-003 | Start Date*: 2012-04-03 |
Sponsor Name:Targacept Inc. | ||
Full Title: A double-blind, placebo-controlled, multicenter, parallel group study to assess efficacy, safety and tolerability of TC-5619 as augmentation therapy to improve negative symptoms and cognition in ou... | ||
Medical condition: Schizophrenia | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: HU (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2014-003076-22 | Sponsor Protocol Number: PSY-201401_ESPRIT | Start Date*: 2016-07-07 | ||||||||||||||||
Sponsor Name:Central Institute of Mental Health Mannheim (ZI) | ||||||||||||||||||
Full Title: Multimodal Prevention of First Psychotic Episode – a 2x2-Factorial Randomized Trial investigating the efficacy of Acetylcysteine (ACC) and Integrated Preventive Psychological Intervention (IPPI) in... | ||||||||||||||||||
Medical condition: Clinical High Risk state for developing a first psychotic episode | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-024202-34 | Sponsor Protocol Number: 24122010 | Start Date*: 2014-04-24 | |||||||||||
Sponsor Name:UNIVERSITÄTSMEDIZIN GÖTTINGEN, GEORG-AUGUST-UNIVERSITÄT,Klinik für Kinder- und Jugendpsychiatrie/Psychotherapie | |||||||||||||
Full Title: Effect of oxytocin on therapy results of a group based social skill training in adolescents with Autism Spectrum Disorder | |||||||||||||
Medical condition: high-functioning autismus spectrum disorders: autistic disorder (F84.0), Asperger syndrome (F84.5), atypical autism (F84.1) | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-001071-11 | Sponsor Protocol Number: 11918A | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:H. Lundbeck A/S | |||||||||||||
Full Title: Randomised, double-blind, parallel-group, placebo-controlled, duloxetine-referenced, dose-finding study of Lu AA24530 in Major Depressive Disorder | |||||||||||||
Medical condition: Major Depressive Disorder | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) SE (Completed) FI (Completed) BE (Completed) AT (Completed) CZ (Completed) FR (Completed) LT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-007019-25 | Sponsor Protocol Number: Delusional Parasitosis 1/Dec 2006 | Start Date*: 2008-01-21 | |||||||||||
Sponsor Name:Barts and the London NHS Trust | |||||||||||||
Full Title: Pilot open trial of efficacy of Risperidone in Delusional Parasitosis | |||||||||||||
Medical condition: Delusional Parasitosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-016715-38 | Sponsor Protocol Number: TEAprotocolversion3-12102009FINAL | Start Date*: 2010-02-08 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:University of Copenhagen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: The TEA Trial- Tolerance and Effect of Antipsychotics in children and adolescents with psychosis An investigator-initiated, phase IV, randomised double-blind multi-centre trial of the benefits and... | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: non-organic and non-drug-induced psychosis, meeting the criteria for ICD-10 diagnoses: F20, F22-F29 and F30.2, F31.2, F31.5, F32.3 and F33.3. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: DK (Completed) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-002213-19 | Sponsor Protocol Number: ELICE-BD-O1 | Start Date*: 2019-09-19 | |||||||||||
Sponsor Name:University of British Columbia | |||||||||||||
Full Title: A 6-Week Randomised, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy of Lurasidone Adjunctive Therapy in Improving Cognitive Functioning in Euthymic Bipolar Disorder Pa... | |||||||||||||
Medical condition: Euthymic Bipolar disorder | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-004172-30 | Sponsor Protocol Number: PREPARE | Start Date*: 2021-10-13 |
Sponsor Name:Charité – Universitätsmedizin Berlin | ||
Full Title: Prevention of paclitaxel-related neurological side effects with lithium – a randomized, double-blind, placebo-controlled, explorative proof-of-concept phase II clinical trial to counteract chemothe... | ||
Medical condition: Breast cancer patients scheduled for treatment with paclitaxel chemotherapy | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: DE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2020-000437-41 | Sponsor Protocol Number: NW-3509/014/II/2019 | Start Date*: 2021-02-24 | |||||||||||
Sponsor Name:NEWRON PHARMACEUTICALS SPA | |||||||||||||
Full Title: A pilot, open-label, rater-blinded, randomized, parallel-group, multi-center study to evaluate the safety, tolerability and preliminary efficacy of three add-on fixed doses of Evenamide in patients... | |||||||||||||
Medical condition: Schizophrenia not responding adequately to current antipsychotic treatment | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-000134-34 | Sponsor Protocol Number: TEAM(B115UCS2019) | Start Date*: 2021-05-24 | |||||||||||
Sponsor Name:ENTE OSPEDALIERO OSPEDALI GALLIERA | |||||||||||||
Full Title: Time restricted Eating And Metformin (TEAM) in invasive breast cancer (IBC) or ductal carcinoma in situ (DCIS). A randomized, phase IIb, window of opportunity presurgical trial. | |||||||||||||
Medical condition: Luminal (ER+ve and/or PgR+ve >=1%) invasive breast cancer not candidate to neo - adjuvant chemotherapy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-002055-15 | Sponsor Protocol Number: J81J1100168007 | Start Date*: 2014-01-28 |
Sponsor Name:UNIVERSITY OF SASSARI | ||
Full Title: RANDOMIZED, CONTROLLED, MULTI-CENTER, INTERNATIONAL CLINICAL STUDY ON THE MOOD-STABILIZING EFFECTS OF MEMANTINE AS AN AUGMENTING AGENT vs. LAMOTRIGINE FOR ONGOING TREATMENT IN BIPOLAR-I DISORDER P... | ||
Medical condition: BIPOLAR I MOOD DISORDERS | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: IT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2012-003209-92 | Sponsor Protocol Number: EVP-6124-016 | Start Date*: 2013-10-22 | ||||||||||||||||
Sponsor Name:Forum Pharmaceuticals, Inc. | ||||||||||||||||||
Full Title: A Randomized, Double-blind, Placebo-controlled, Parallel, 26 Week, Phase 3 Study of 2 Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo as an Adjunctive Pro-cogniti... | ||||||||||||||||||
Medical condition: Cognitive impairment associated with schizophrenia | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) IT (Completed) PL (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2012-003208-10 | Sponsor Protocol Number: EVP-6124-015 | Start Date*: 2013-06-28 | ||||||||||||||||
Sponsor Name:Forum Pharmaceuticals Inc. | ||||||||||||||||||
Full Title: A Randomized, Double-blind, Placebo-controlled, Parallel, 26 Week, Phase 3 Study of 2 Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo as an Adjunctive Pro-cogniti... | ||||||||||||||||||
Medical condition: Cognitive impairment associated with schizophrenia | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) ES (Completed) PL (Completed) | ||||||||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
